1-(3-thienyl)-N-(3-thienylmethyl)methanamine | 851768-42-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-(3-thienyl)-N-(3-thienylmethyl)methanamine
• 英文别名: bis(thiophen-3-ylmethyl)amine；1-thiophen-3-yl-N-(thiophen-3-ylmethyl)methanamine
• CAS: 851768-42-8
• 化学式: C₁₀H₁₁NS₂
• mdl: MFCD08752871
• 分子量: 209.336
• InChiKey: XTHUEYDCVKOMAL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  68.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-氰基噻吩 在 ammonia borane 、 C₁₆H₂₉Cl₂CoN₂P 作用下， 反应 13.0h， 以78%的产率得到1-(3-thienyl)-N-(3-thienylmethyl)methanamine
  参考文献：
  名称：

  腈的轻度和选择性钴催化化学发散转移加氢

  摘要：

  在本文中，我们描述了腈的选择性钴催化化学发散转移氢化反应，以合成伯，仲和叔胺。溶剂效应对于选择性控制起着关键作用。该方法的普遍适用性以高化学选择性合成了70多种带有各种官能团的胺产物而得到了强调。此外，这种温和的系统实现了腈转移氢化的> 2000吨（周转数）。

  DOI：

  10.1002/anie.201608345

文献信息

• Mild and Selective Cobalt‐Catalyzed Chemodivergent Transfer Hydrogenation of Nitriles
  作者：Zhihui Shao、Shaomin Fu、Mufeng Wei、Shaolin Zhou、Qiang Liu

  DOI：10.1002/anie.201608345

  日期：2016.11.14

  Herein, we describe a selective cobalt‐catalyzed chemodivergent transfer hydrogenation of nitriles to synthesize primary, secondary, and tertiary amines. The solvent effect plays a key role for the selectivity control. The general applicability of this procedure was highlighted by the synthesis of more than 70 amine products bearing various functional groups in high chemoselectivity. Moreover, this

  在本文中，我们描述了腈的选择性钴催化化学发散转移氢化反应，以合成伯，仲和叔胺。溶剂效应对于选择性控制起着关键作用。该方法的普遍适用性以高化学选择性合成了70多种带有各种官能团的胺产物而得到了强调。此外，这种温和的系统实现了腈转移氢化的> 2000吨（周转数）。
• AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS
  申请人：Argade Ankush Baburao

  公开号：US20090227566A1

  公开（公告）日：2009-09-10

  This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor. An example of a compound of formula (I) is (a).

  本发明涉及公式(I)的化合物(或其药学上可接受的盐或前药)、其制药组合物以及其作为Xa因子和/或凝血酶抑制剂的用途，以及其制备过程和中间体。公式(I)的化合物的一个例子是(a)。
• AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS
  申请人：Biediger Ronald J.

  公开号：US20130236434A1

  公开（公告）日：2013-09-12

  A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

  一种增强细胞与整合素结合配体的结合的方法包括在体外用整合素激动剂处理表达整合素的细胞，其中整合素选自α4β1、α5β1、α4β7、αvβ3和αLβ2群，然后将处理后的细胞与整合素结合配体接触；具有一般式I的整合素激动剂化合物；使用这种激动剂治疗表达整合素的细胞以增强结合的方法；以及包括将激动剂处理的细胞或激动剂化合物给哺乳动物的治疗方法。
• AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS
  申请人：TEXAS HEART INSTITUTE

  公开号：US20150368234A1

  公开（公告）日：2015-12-24

  A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

  一种增强细胞与整合素结合配体结合的方法包括在体外用整合素激动剂处理表达整合素的细胞，其中整合素被选择自α4β1、α5β1、α4β7、αvβ3和αLβ2组成的群体中的一种，并将处理后的细胞与整合素结合配体接触；具有一般式I的整合素激动剂化合物；用这样的激动剂处理表达整合素的细胞以增强结合的方法；以及包括向哺乳动物施用经激动剂处理的细胞或激动剂化合物的治疗方法。
• Agonists that enhance binding of integrin-expressing cells to integrin receptors
  申请人：Texas Heart Institute

  公开号：EP2881392A1

  公开（公告）日：2015-06-10

  A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

  一种增强细胞与整合素结合配体结合的方法，包括在体外用整合素的激动剂处理表达整合素的细胞，其中整合素选自由α4β1、α5β1、α4β7、αvβ3和αLβ2组成的组，并使处理过的细胞与整合素结合配体接触；具有通式Ⅰ的整合素激动剂化合物；用这种激动剂处理整合素表达细胞以增强结合的方法；以及治疗方法，包括给哺乳动物施用激动剂处理过的细胞或激动剂化合物。